Positive Data from the First Part of IRLAB's Phase I Study with the Drug Candidate IRL757

a company discovering and developing novel treatments for Parkinson's disease - today announces that the company has successfully completed the first part of its Phase I clinical trial with single ascending doses (SAD) of the drug candidate IRL757, …
Jetzt den vollständigen Artikel lesen